| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22019 |
| Drug | Defatted powder of Arachis hypogaea L., semen (peanuts) |
| Brand | Palforzia® |
| Indication | For the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet. |
| Assessment Process | |
| Rapid review commissioned | 01/04/2022 |
| Rapid review completed | 04/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Palforzia® compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/05/2022 |
| Pre-submission consultation with Applicant | 22/11/2022 |
| Full submission received from Applicant | 06/01/2023 |
| Preliminary review sent to Applicant | 31/05/2023 |
| NCPE assessment re-commenced | 29/06/2023 |
| Factual accuracy sent to Applicant | 27/10/2023 |
| NCPE assessment re-commenced | 06/11/2023 |
| NCPE assessment completed | 29/11/2023 |
| NCPE assessment outcome | The NCPE recommends that Palforzia® not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.